// App-Quantinova.ai

M2183 2016 AHA : Real-World Comparisons of Major Bleeding Risk for Commercially Insured Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin

Researchers

Presenter

  • Allison Keshishian

Principal Investigators

  • Lien Vo

  • Jack Mardekian

  • Shalabh Singhal

  • Chad Patel

  • Kevin Odell

  • Jeffrey Trocio

Medical Centers

  • Univ of California, Irvine, CA

  • STATinMED Research, Ann Arbor, MI

Locations

  • United States

Companies

  • Pfizer Inc.

  • Bristol-Myers Squibb

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Non-valvular atrial fibrillation

  • Cardiac valvular dysplasia X-linked

  • Venous thrombosis

  • Arrhythmia

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • rivaroxaban

  • Pradax

  • apixaban

  • Warfarin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved